✦ LIBER ✦

Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma

✍ Scribed by Maurie Markman; Stephen Cleary; Craig Pfeifle; Stephen B. Howell

Publisher: John Wiley and Sons
Year: 1986
Tongue: English
Weight: 382 KB
Volume: 58
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19860701)58:1<18::aid-cncr2820580105>3.0.co;2-c

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dihydro-5-azacytidine and cisplatin in t

Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma : A phase II study by the Cancer and Leukemia Group B

✍ Brian L. Samuels; James Herndon II; David C. Harmon; Robert Carey; Joseph Aisner 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 3 views

## BACKGROUND. In a prior Cancer and Leukemia Group B (CALGB) Phase II trial of

Reduction of the systemic toxicity of ci

Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies

✍ Akiva M. Vexler; Xiaode Mou; Alberto A. Gabizon; Raphael Gorodetsky 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 572 KB

## Abstract Cisplatin (CDDP) administration by the intra‐arterial hepatic route (i.a.h.) in patients with primary or metastatic liver malignancies could enhance the anti‐tumor activity of the drug and reduce its systemic toxicity. The aim of the present study was to compare Pt pharmacokinetics and